Lifastuzumab vedotin

Drug Profile

Lifastuzumab vedotin

Alternative Names: Anti-NaPi2b; DNIB-0600A; NaPi2b-ADC; NaPi3b; RG-7599; RO-5541081

Latest Information Update: 13 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Genentech
  • Class Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors; Type IIb sodium-phosphate cotransporter protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Fallopian tube cancer; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer

Most Recent Events

  • 01 May 2016 Genentech completes a phase-I clinical trial in Ovarian cancer and Non-small cell lung cancer (Second-line therapy or greater, Late-stage disease, Metastatic disease) in USA and Spain (IV) (NCT01363947)
  • 31 May 2014 Efficacy data from a phase I trial in Ovarian cancer or Non-small cell lung cancer presented at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO-2014)
  • 22 Nov 2013 Phase-I clinical trials in Ovarian cancer (combination therapy, in platinum-sensitive disease) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top